ImmunityBio, Inc. (IBRX)

ImmunityBio Revenue

ImmunityBio had revenue of $302.00K in the twelve months ending March 31, 2024, down -48.46% year-over-year. Revenue in the quarter ending March 31, 2024 was $40.00K, a -88.89% decrease year-over-year. In the year 2023, ImmunityBio had annual revenue of $622.00K with 159.17% growth.

• Revenue (ttm): $302.00K
• Revenue Growth: -48.46%
• P/S Ratio: 14,151.95
• Revenue / Employee: $481
• Employees: 628
• Market Cap: 4.27B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	622.00K	382.00K	159.17%
Dec 31, 2022	240.00K	-694.00K	-74.30%
Dec 31, 2021	934.00K	329.00K	54.38%
Dec 31, 2020	605.00K	-1.60M	-72.52%
Dec 31, 2019	2.20M	2.16M	4,585.11%
Dec 31, 2018	47.00K	2.00K	4.44%
Dec 31, 2017	45.00K	1,000.00	2.27%
Dec 31, 2016	44.00K	-192.00K	-81.36%
Dec 31, 2015	236.00K	-405.00K	-63.18%
Dec 31, 2014	641.00K	41.00K	6.83%
Dec 31, 2013	600.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.